Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib (M1774) Mass Balance and Absolute Bioavailability in Advanced Solid Tumors
NCT06308263Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tuvusertib in solid tumor (3 arms), sponsored by Merck KGaA. Primary endpoints: Percent Urinary Recovery Of Total Radioactivity up to 336 hours, Percent Fecal Recovery Of Total Radioactivity up to 336 hours and 8 more. Started Mar 2024; status: completed.
02
Drugs
tuvusertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06308263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308263.